A 71-year-old woman was referred to the Department of Ophthalmology and Visual Science, Yale University, for an evaluation of decreased vision, worsening night vision, and peripheral vision loss in the left eye of 3 months' duration. She had a history of right ductal breast carcinoma in 1993 that was treated with a lumpectomy and radiation, with no known metastases. She also had a stage II-A melanoma of the left arm excised in 2011, gout, and hypertension. She denied flashes, floaters, or eye pain and had no history of eye surgery or eye trauma. Family history of eye disease was noncontributory.
Examination
On initial presentation, best-corrected visual acuity measured 20/20+ in each eye. Three months later, on presentation at Yale University, visual acuities were 20/25 +2 in the right eye and at 20/30 −1 in the left eye. Anterior segment examination in each eye was unremarkable except for 1+ nuclear sclerotic cataract in the right eye and trace cortical cataract in the left eye. Pupils were round and equally reactive, and there was no relative afferent pupillary defect. Ishihara plates were 14/14 in each eye. Ocular motility was full, and the patient was orthotropic.
Dilated fundus examination of the right eye showed no vitreous cells, a titled, sharp, pink optic nerve, and a flat macula with a good foveal reflex. In the left eye, there were 2+ vitreous cells with a tilted optic nerve with temporal pallor and a trace epiretinal membrane in the macula. Both optic nerves had a cup-to-disc ratio of 0.1. Retinal vasculature in both eyes showed mild arteriolar attenuation.
Goldmann visual field testing of the right eye showed I-4e reduced to 20° circumferentially and V-4e with mild reduction superiorly to 50° and mild reduction temporally to 70° ( Figure 1A) ; in the left eye, I-3e reduced to 10° circumferentially and III-4e and V-4e moderately reduced to 35°-40° superiorly and reduced inferiorly to 55°-60° ( Figure 1B ).
Ancillary Testing
Magnetic resonance imaging of the brain with and without contrast was negative for metastatic disease. No further genetic tests for neoplasm were recommended by the oncology team. A positron emission tomography computerized tomography (CT) scan showed hypermetabolic uptake in a 4.8 cm left axillary lymph node without any other pathologic uptake. A left axillary lymph node dissection revealed involvement of one lymph node for melanoma, whereas six additional lymph nodes were negative for metastatic disease.
Treatment
After the diagnosis of melanoma-associated retinopathy was made, our patient was treated with intravenous immunoglobulin (2 mg/kg) for 6 months, resulting in her having a stable visual acuity (20/30 ± 2 in each eye). Of note, an improvement in her night vision was observed subjectively; however, repeat ffERG findings were unchanged.
Differential Diagnosis
Our differential diagnosis included intraocular lymphoma, melanoma-associated retinopathy (MAR), CAR, and metastatic disease.
Diagnosis and Discussion
CAR and MAR are both rare paraneoplastic syndromes that can be distinguished by clinical symptoms, fundus characteristics, and electrophysiology findings. Smallcell lung cancer has been most frequently reported as the primary cancer in CAR; breast and endometrial cancers have also been reported but less frequently. 1 CAR typically presents with loss of central vision, reduced color vision, a ring scotoma, photopsias, and decreased awave and b-wave on ffERG. 2 MAR typically presents with rapid onset of photopsias, scotomata, decreased night vision, and variable loss of peripheral or paracentral vision. 3, 4 Our patient had positive antiretinal autoantibodies against the 46-kDa enolase protein, which is also associated with CAR; but, positive antiretinal autoantibodies are also found in 10% of healthy patients and in various autoimmune diseases. 5 Our patient did not have any other paraneoplastic or antiretinal autoantibodies. The ffERG finding helped confirm the diagnosis of MAR. The proposed pathophysiology of MAR is due to antibodies which target the depolarizing bipolar cells. 6 In MAR, the photopic ffERG shows a decreased b-wave with a relatively normal awave, whereas the scotopic ffERG shows a markedly decreased b wave with decreased b/a wave ratio. In CAR, on the other hand, the photopic and scotopic ffERG shows a decreased a-wave and decreased bwave. 7 Both of these paraneoplastic syndromes can be treated with immunomodulation. Our patient was treated with intravenous immunoglobulin. 8 Although no large randomized trials exist, visual improvement in CAR has been reported in the majority of patients receiving corticosteroid treatment, although it has been noted that some patients with autoimmune retinopathies have improved with a combination of plasmapheresis and corticosteroid therapy. 1 Visual loss in patients with a cancer history may be due paraneoplastic syndromes, treatment toxicity and ocular metastases. In addition to clinical evaluation, serologies and electrophysiology testing are important to establish a diagnosis. A diagnosis of a paraneoplastic disease should prompt evaluation of a patient for a primary cancer, metastatic disease, or progressing systemic cancer.
